Novo Nordisk CagriSema Trial Shows 25% Weight Loss in Women
Phase 3 results for investigational CagriSema showed an average 25% body-weight decrease after 68 weeks in more than 2,300 overweight or obese women.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.